MDLN (Medline) Research & Development: $0 Mil (TTM As of Mar. 2026)


MDLN Medline Inc MDLN
16 GF Score
Price $38.82
! 3 Warning Signs
View Full Analysis

What is Medline Research & Development?

Medline MDLN +2.79% 16 Research & Development is $0 Mil as of Mar. 2026. GuruFocus rates MDLN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medline's Research & Development for the three months ended in Mar. 2026 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

Medline  (NAS:MDLN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medline Research & Development Related Terms

Medline Research & Development Historical Data

* Premium members only.

The historical data trend for Medline's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medline Research & Development Chart

Medline Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 0.00 0.00 0.00

Medline Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDLN
16GF Score
Medline Inc MDLN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medline Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
Medline (MDLN) has a Research & Development of $0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medline and its competitors.
Is Medline's Research & Development too high?
Medline's current Research & Development is $0 Mil. Overall, Medline has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Medline's Research & Development compare to RMD and WST?
Medline's Research & Development of $0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medline and its competitors. Medline's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medline stock overvalued right now?
Medline (MDLN) has a current Research & Development of $0 Mil. The current Research & Development is $0 Mil. Medline's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medline (MDLN), the current Research & Development is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medline Business Description

Other Exchanges L10:Germany
Address 3 Lakes Drive, Northfield, IL, USA, 60093
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
16GF Score

Get the complete analysis for MDLN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.82
Price